Assembly Biosciences (ASMB) Stock Price

Assembly Biosciences Price

NASDAQ·CLOSED
23.09
​
Market closed

Revenue has compounded at 29.7% per year over the past 8 years to 72.30 M USD. Assembly Biosciences's net margin stands at -8.5%, up from -78.6% several years earlier. Analysts set a median price target of 47.50 USD, implying 105.7% above the current price. Of 10 analysts, 9 rate the stock a buy — an overall Buy consensus.

Assembly Biosciences stock price

Access this data via the Eulerpool API

Assembly Biosciences business model & stock analysis

Assembly Biosciences, Inc. is a biotechnology company, which engages in the development of products for infectious diseases, such as chronic hepatitis B virus and illnesses associated with a dysbiotic microbiome. The company is headquartered in South San Francisco, California and currently employs 139 full-time employees. The company went IPO on 2010-12-17. The firm is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome. The company has discovered various core protein Allosteric Modulators (CpAMs), which are small molecules that directly target and allosterically modulate the HBV core (HBc) protein. Its Microbiome Program consists of an integrated platform that includes a strain identification and selection process, methods for strain isolation and growth under current good manufacturing practice conditions, and a delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal (GI) tract. The lead product candidate from this platform, AB-M101, is in development for the treatment of clostridium difficile-infections.

Frequently asked questions about Assembly Biosciences

Analysts currently set an average price target of 47.50 USD for the Assembly Biosciences stock (median: 47.50 USD), implying +105.7 % versus the latest price. The consensus is based on 10 analyst ratings.

10 analysts currently rate the Assembly Biosciences stock: 9 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Assembly Biosciences to generate revenue of 63.43 M USD and earnings per share of -0.86 USD.

Converted at the current exchange rate, the Assembly Biosciences share trades at 20.61 EUR (23.09 USD).

The Assembly Biosciences share (ASMB) is listed on 4 stock exchanges, including: NASDAQ (ASMB), Frankfurt (V7B1.F), München (V7B1.MU), Düsseldorf (V7B1.DU).

The expected revenue of Assembly Biosciences is 63.43 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Assembly Biosciences is -9.62 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Assembly Biosciences is currently -26.90. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Assembly Biosciences stock.

The price-to-sales ratio (P/S) of Assembly Biosciences is currently 4.08. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Assembly Biosciences stock.

The Eulerpool Quality Score for Assembly Biosciences is 3/10.

The ISIN of Assembly Biosciences is US0453962070. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Assembly Biosciences is A117S1. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Assembly Biosciences is ASMB. The ticker symbol is used to trade Assembly Biosciences shares on the stock exchange.

Fair ValueTerminal
21.24 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue per Employee
990,452.05 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Currency
USD
Initial public offering
Dec 17, 2010
ISIN
US0453962070
Cusip
045396108
Sedol
BP4WW00
Market capitalization
365.28 M USDSmall Cap
52-Week Range
PEG
-2.10
P/E ratio
P/Ee 2026
-26.90
P/Ee 2027
-5.37
P/Ee 2028
-8.38
P/Ee 2029
-5.29
P/Ee 2030
-10.77
P/S
P/Se
4.08
EV/EBIT
—
P/B Ratio
1.77
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-2.95 %
Last updated Oct 10, 2026, 10:05 AM

Assembly Biosciences Ticker

DÜSSELDORF · V7B1.DUFRANKFURT · V7B1.FMUNICH · V7B1.MUNASDAQ · ASMB